Jan 17 2018
For the first time, MSCO brings together oncology professionals and research scientists from Macau, Hong Kong and Guangzhou to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
MSCO was established in 2016. The initial idea to establish this society, was in my mind in recent years. As a medical oncologist, and I know basic scientific research is very important for clinical practice. I visited the University of Macau (UM) and the Macau University of Science and Technology (MUST) for more collaboration. I meet Elaine and we begun to operate on cancer research.
We agree that there are many outstanding scientists, physician, and researchers among Macau, Hong Kong, and mainland China. It’s worth to get these healthcare professionals together and create synergistic effects to accelerate the clinical development of cancer treatment.
The theme of the 2017 MSCO Annual Meeting is immunotherapy and precision medicine: opportunity of Macau. We aimed at introducing the clinical and basic research conducted in Macau, especially in KWH and MUST. Dr. Yabing Cao shared his opinion on concurrent conditions on immune therapy, highlights what we have known and what we don’t known. Since early 2015, there has been more than 300 patients that received PD-1 therapy in KWH. Dr. Cao summaries characteristics of patients and also patterns of their response. Five topics was discussed in his topic, including the best sequential of IO and chemo combination, the relation between PD-1 and EGFR, the difference between PD-L! and PD-1 inhibitors, and the recent discussed hyperprogression phenomenon.
Prof. Carmen Wong is Assistant Professor at the Department of Pathology of HKU. Her study was focus on understanding the metabolism and molecular signatures of liver cancer. She gives a topic on PD-1 blockage therapy in liver cancer.
Prof. Elaine Leung is from Applied Research in Medicine and Health Macau Institute of Science and Technology (MUST). She briefly introduced the work and achievements they have made in Macau. She has more than 20 high IF SCI papers in 2017. Now Elaine and I are on cooperation with lung cancer.
Prof. Yizhun Zhu is dean of School of Pharmacy, MUST. He is aim to cultivate local pharmaceutical talents, improve local drug research and development capabilities, and provide a new pasture for developing leading pharmaceutical talents for China and the world. In his speech he talked the story on the journal in traditional Chinese medicine development and finally successful launch in marketing.
Dr. Tongyu Lin joined our seminar and talked about how Macau utilize it’s advantage in clinical oncology practice and research. First of all, we need cooperate on research. Now we have a strong connection in samples sharing. Next, we should highlight the importance of NGS or third generation sequencing, hope find mechanism of resistance.
This meeting is an useful attempt for us, with limited human resource and time. However, we will keep going to find the way for Macau physician and scientist that will make huge success in future.